BioMarin Pharma (BMRN) Posts Q4 Loss of $0.03/Share
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $58.99 +2.02%
EPS Growth %: -34.0%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
CRMT, PKE, More
EPS Growth %: -34.0%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 GAAP EPS of ($0.03), which may not compare to the analyst estimate of ($0.24). Revenue for the quarter came in at $353.2 million versus the consensus estimate of $377.35 million.
GUIDANCE:
BioMarin Pharma sees FY2019 revenue of $1.68-1.75 billion, versus the consensus of $1.73 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- UBS Upgrades Charoen Pokphand Foods (CPF:TB) to Buy
- Rivian raises 2026 delivery outlook after Q2 results top guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
